Characterising the Role of a Putative Mammalian Aspartate Dehydrogenase In

Total Page:16

File Type:pdf, Size:1020Kb

Characterising the Role of a Putative Mammalian Aspartate Dehydrogenase In Characterising the Role of a Putative Mammalian Aspartate Dehydrogenase in Hepatic Lipogenesis and Secretion of Very Low Density Lipoproteins STEPHANIE ANN BONNEY Thesis submitted to the Imperial College of London For the degree of Doctor of Philosophy December 2009 MRC Genomic and Molecular Medicine Clinical Sciences Centre Imperial College School of Medicine Hammersmith Hospital, Du Cane Road London W12 ONN, UK. 1 i Acknowledgements I owe much gratitude to my Ph.D. supervisor, Professor Carol Shoulders for providing me the opportunity, support, advice, guidance and strength to undertake and complete a Ph.D. I would like to thank the many people who have significantly contributed to my studies and helped me along my way: Rocio Lale-Montes, Angela Whyte, Christopher Mann, Penny Ritchie, Abdul Hebbachi, Geoffrey Gibbons, Bethan Jones, Emma Jones and Max Salm. I am indebted to my many colleagues for providing a stimulating and fun environment in which to learn and grow. I am especially grateful to Helen Ringham, Claire Hutchison, Ruth Newton, Margaret Town, Paul Williams, Muddassar Mirza, Stuart Horswell and Lee Fryer. I wish to thank my family and friends for helping me get through the difficult times, and for all the emotional support, comradery, entertainment, and caring they provided. Especially to my mother Sylvia Bonney, who provided consistent support and encouragement through-out the many years of my Ph.D. To my brothers Craig, John and Sean, my sister in-laws Tracey, Francine and Suey and to all my nieces and nephews thank you for being there and supporting me through out the years. To all my friends, especially Denise Read, Victoria Westhead, Julia Barnett and Sophie Voline who have all been so supporting and caring through out the whole experience. Lastly, and most importantly, I wish to thank my husband, James Morton for giving the support to see the Ph.D. through to completion and for proof-reading all 251 pages of the thesis. I love you with all my heart. I dedicate this thesis to my father William Raymond Bonney, whose loving memory has guided my through the tough times and provided me with the strength to complete - you were my leading light. 2 ii Preface Publications relevant to this thesis are; Griffin,J.L., Bonney,S.A., Mann,C., Hebbachi,A.M., Gibbons,G.F., Nicholson,J.K., Shoulders,C.C., and Scott,J. (2004). An integrated reverse functional genomic and metabolic approach to understanding orotic acid-induced fatty liver. Physiol Genomics 17, 140-149. Hebbachi,A.M., Seelaender,M.C., Baker,B.W., and Gibbons,G.F. (1997). Decreased secretion of very-low-density lipoprotein triacylglycerol and apolipoprotein B is associated with decreased intracellular triacylglycerol lipolysis in hepatocytes derived from rats fed orotic acid or n-3 fatty acids. Biochem. J. 325 ( Pt 3), 711-719. Yang,Z., Savchenko,A., Yakunin,A., Zhang,R., Edwards,A., Arrowsmith,C., and Tong,L. (2003). Aspartate dehydrogenase, a novel enzyme identified from structural and functional studies of TM1643. J. Biol. Chem. 278, 8804-8808. 3 iii Abstract Hepatic lipogenesis and the secretion of very low-density lipoproteins are severely perturbed in orotic-acid fed rats. Proteomic analysis of this rodent fatty liver identified a protein enriched in the microsomal fraction. The protein contains a domain of unknown function 108 (DUF 108) and is found to compose a complete protein in archaebacteria and mammalian species, but a single domain in Caenorhabditis elegans protein Q19527. The cDNA for human protein A6ND91 was cloned and stable rat hepatoma cell lines, expressing recombinant A6ND91-FLAG tagged protein were produced. Significant increases in de-novo lipogenesis and secretion of triglyceride-enriched lipoproteins were observed. This thesis considers A6ND91 protein in terms of structure and proposed function. Previous work has indicated that the homologous protein Thermatoga maritime 1643 (TM1643) possesses NAD+ or NADP+-dependent dehydrogenase activity towards L-Aspartate, producing NADH or NADPH plus iminoaspartate, a substrate that rapidly degrades into oxaloacetate (OAA) and ammonia. In this thesis, analyses of primary and predicted secondary structure of A6ND91 and TM1643 revealed that residues binding NAD+/NADP+ and the proposed active catalytic residue, Histidine198, are conserved. Northern-blot analysis identified A6ND91 is highly expressed in human liver, moderately in kidney, and at low levels in the brain. Western-blot analysis identified that A6ND91 is predominately localised to the cytosol, with minimal amounts in the microsomal fraction. Proteomic analysis revealed that A6ND91 contains a phosphorylated residue, Serine168. The kinase potentially responsible for phosphorylation of the residue is Glycogen Synthase Kinase 3 (GSK3), a well- characterised enzyme involved in regulation of glycogen metabolism and acetyl-CoA production. Microarray analyses indicate that over-expression of A6ND91 perturbs activity of several metabolic pathways involved in carboxylic acid metabolism, cholesterol synthesis and complement activation. Closer inspection of the perturbed metabolic pathways revealed an overlap through the substrates OAA/pyruvate/acetyl-CoA. 4 Assays were performed to establish the NAD+/NADH and NADP+/NADPH redox state in cell lines expressing A6ND91. Results established that NAD+/NADH ratio was significantly reduced, suggesting that A6ND91 may operate as a dehydrogenase. Collectively, results suggest that L-Aspartate dehydrogenase activity of TM1643 is conserved in human A6ND91, playing a key role in hepatic lipid and energy metabolism through the production of OAA and its subsequent conversion to pyruvate/acetyl-CoA and cholesterol. 5 iv Contents Page No. i Acknowledgements 2 ii Preface 3 iii Abstract 4 iv Contents 6 v List of Figures 12 vi List of Tables 16 vii List of Appendices 18 viii Abbreviations 19 1.0 Chapter 1 Introduction 22 1.1 General Introduction 22 1.2 Metabolism of Amino Acids and Impact on Lipogenesis 22 1.3 Orotic Acid and Fatty Liver 32 1.4 Identification of Mammalian DUF 108 Protein 36 1.5 Aims 42 2.0 Chapter 2. Materials and Methods 43 2.1 General Molecular and Protein Materials and Methods 43 2.1.1 Human and Rat Tissue 43 2.1.2 Generation of Rabbit Polyclonal Human A6ND91-FLAG 43 Antibody 2.1.3 Cellular Homogenisation 44 2.1.4 Protein Solubilisation and Quantification 45 6 2.1.5 Shrimp Alkaline Phosphatase (SAP) Assay 45 2.1.6 SDS-PAGE 45 2.1.7 Two-Dimensional (2D) Iso-Electric Focusing (IEF) 46 2.1.8 Matrix-Assisted Laser Desorption Ionization (MALDI) MS 46 2.1.9 HPLC Electrospray Tandem MS 47 2.1.10 Western Blotting 47 2.2 Characterisation of Human A6ND91-FLAG 48 2.2.1 Generation of Human A6ND91-FLAG Probe 48 2.2.2 Probe Labelling and Northern Blot 50 2.2.3 In-vitro Expression of Human A6ND91-FLAG 51 2.2.4 NAD: NADH and NADP: NADPH Assays 52 2.2.5 ATP: ADP Assays 53 2.3 Cloning and Expression of EDM07494-FLAG 54 2.3.1 Construction of EDM07494-FLAG cDNA 54 2.3.2 Purification of Amplified EDM07494-FLAG cDNA 55 2.3.3 Restriction Enzyme Digestion of EDM07494-FLAG cDNA and 55 PcDNA4/TO Vector 2.3.4 Ligation of PcDNA4/TO vector EDM07494-FLAG cDNA 55 2.3.5 Transformation of TOP10 bacterial cells with Plasmid DNA 56 2.3.6 Growth of Transformed Bacterial Colonies 56 2.3.7 Screening Constructs for EDM07494-FLAG Insert 58 2.3.8 High Yield Growth and Purification of EDM07494-FLAG 58 Construct 7 2.3.9 Stable Cell line Rat 58 2.3.10 Isolation of Colonies 59 2.4 Microarray Methods 59 2.4.1 RNA Extraction 59 2.4.2 Quantitative and Qualitative Assessment of RNA 60 2.4.3 First-Strand cDNA synthesis 61 2.4.4 Second-Strand cDNA synthesis 61 2.4.5 Preparation of cRNA 62 2.4.6 Hybridisation and Staining Procedures 62 2.4.7 GeneChip Wash and Staining Procedure 63 2.4.8 Analysis of Gene Chip Data 63 2.4.9 Principle Component Analysis (PCA) 64 2.4.10 Identifying Differentially Expressed Genes 65 2.4.11 Annotation of Unknown Expressed Sequence Tags (ESTs) 65 2.4.12 Gene Ontology (GO) 65 2.4.13 Real Time RT-PCR 65 2.1.14 KEGG PATHWAY 66 3.0 Chapter 3. Characterisation of Human A6ND91 and Rat EDM07494 68 3.1 Introduction 68 3.2 Results 75 3.2.1 Protein Alignment of DUF 108 family 75 3.2.2 Expression of A6ND91 in Human Tissue 75 8 3.2.3 Characterization of Human A6ND91-FLAG Polyclonal 75 Antibody 3.2.4 In vitro expression of A6ND91-FLAG and Rat EDM07494- 79 FLAG 3.2.5 Post Translational Modification of Human A6ND91-FLAG and 83 Rat EDM07494-FLAG 3.2.6 A6ND91 is Predominantly Cytosolic 91 3.2.7 NAD: NADH and NADP: NADPH assay 91 3.2.8 ATP: ADP Ratio in A6ND91-FLAG expressing Cells 94 3.3 Discussion 98 4.0 Chapter 4. Microarray and RTPCR in Cells Expressing A6ND91 104 4.1 Introduction 104 4.2 Results 107 4.2.1 Expression of Human A6ND91-FLAG as identified by 107 Western Blot 4.2.2 Quality Control of total RNA, cDNA and cRNA 107 4.2.3 Hybridisation to Affymetrix GeneChip Rat Genome 230 2.0 112 Array 4.2.4 Quality of Hybridisation 112 4.2.5 Normalisation of data using CARMAWeb 119 4.2.6 Differentially expressed probe sets identified by Principle 119 Component Analysis (PCA) and Significance Analysis of Microarrays (SAM). 4.2.7 Human A6ND91-FLAG RNA expression 122 4.2.8 Functional annotation 122 9 4.2.9 GO Classification 122 4.2.10 Real Time RT-PCR 124 4.3 Discussion 129 5.0 Chapter 5. Perturbed Metabolic Pathways in Cells Expressing 134 A6ND91 5.1 Introduction 134 5.2 Results 136 5.2.1 Mapping Differentially Expressed Genes to Metabolic 136 Pathways 5.2.2 Cholesterol and Steroid Metabolism 136 5.2.3 Xenobiotic Metabolism 143 5.2.4 Carboxylic Acid Metabolism 146 5.2.4.1 Amino Acid Metabolism 157 5.2.4.2 Alanine and Aspartate 157 5.2.4.3.
Recommended publications
  • ASSESSING DIAGNOSTIC and THERAPEUTIC TARGETS in OBESITY- ASSOCIATED LIVER DISEASES Noemí Cabré Casares
    ASSESSING DIAGNOSTIC AND THERAPEUTIC TARGETS IN OBESITY- ASSOCIATED LIVER DISEASES Noemí Cabré Casares ADVERTIMENT. L'accés als continguts d'aquesta tesi doctoral i la seva utilització ha de respectar els drets de la persona autora. Pot ser utilitzada per a consulta o estudi personal, així com en activitats o materials d'investigació i docència en els termes establerts a l'art. 32 del Text Refós de la Llei de Propietat Intel·lectual (RDL 1/1996). Per altres utilitzacions es requereix l'autorització prèvia i expressa de la persona autora. En qualsevol cas, en la utilització dels seus continguts caldrà indicar de forma clara el nom i cognoms de la persona autora i el títol de la tesi doctoral. No s'autoritza la seva reproducció o altres formes d'explotació efectuades amb finalitats de lucre ni la seva comunicació pública des d'un lloc aliè al servei TDX. Tampoc s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant als continguts de la tesi com als seus resums i índexs. ADVERTENCIA. El acceso a los contenidos de esta tesis doctoral y su utilización debe respetar los derechos de la persona autora. Puede ser utilizada para consulta o estudio personal, así como en actividades o materiales de investigación y docencia en los términos establecidos en el art. 32 del Texto Refundido de la Ley de Propiedad Intelectual (RDL 1/1996). Para otros usos se requiere la autorización previa y expresa de la persona autora. En cualquier caso, en la utilización de sus contenidos se deberá indicar de forma clara el nombre y apellidos de la persona autora y el título de la tesis doctoral.
    [Show full text]
  • Kinetics of Ornithine Carbamoyltransferase
    15// 454 BIOCHEMICAL SOCIETY TRANSACTIONS Ammonia stimulation of malate dehydrogenase from Bacilllls slearolhermophillls: generation of an apparent aspartate dehydrogenase activity C. N. G. SCHMIDT* and L. JER VISt Attempts to purify aspartate dehydrogenase by salt fraction• • Departmel/t 0/ Botal/Y. Rothamsted Experimel/tal Statiol/. ation. chromatography on Cibacron Blue 3GA-Sepharose or \ Harpel/del/. Herts. A L5 2JQ. U.K .. al/d t Departmel/t 0/ Procion Red HE-3B-Scpharose. affinity chromatography on Biology. Paisley College o/Tee/mology. High Street. Paisley 5'-AMP-Sepharose and gel filtration through Sephacryl S-300 PA I 2BE. Re/l(rewshire. Seollal/d. U.K. always resulted in co-purification of malate dehydrogenase. ' Purification of malate dehydrogenase to near-Ifomogeneity by During investigations into the enzymology of ammonia assimi• the procedure of Wright & Sundaram (1979) yielded a product lation by Baeil/lls stearolhermophillls strain PH24 (Buswell & that was more than 90% pure but still appeared to contain Twomey. 1975). we detected high amounts of an apparent aspartate dehydrogenase in that the addition of ammonia to the aspartate dehydrogenase activity. The enzyme appeared to be malate dehydrogenase assay system caused a 2-fold increase in capable of catalysing the reductive ami nation of oxaloacetic acid the rate of NADH oxidation. Attempts to stain polyacrylamide with NA DH as cofactor. but could not catalyse the oxidative gels for aspartate dehydrogenase activity by using I.-aspartate. deamination of I.-aspartic acid. At low concentrations of NI~4C1 NAD+., Nitro Blue Tetrazolium and phenazonium metho• as the sole nitrogen source in the culture medium. the most sulphate were unsuccessful.
    [Show full text]
  • C12) United States Patent (IO) Patent No.: US 10,774,349 B2 San Et Al
    I1111111111111111 1111111111 111111111111111 IIIII IIIII IIIII IIIIII IIII IIII IIII US010774349B2 c12) United States Patent (IO) Patent No.: US 10,774,349 B2 San et al. (45) Date of Patent: Sep.15,2020 (54) ALPHA OMEGA BIFUNCTIONAL FATTY 9/1029 (2013.01); C12N 9/13 (2013.01); ACIDS C12N 9/16 (2013.01); C12N 9/88 (2013.01); C12N 9/93 (2013.01) (71) Applicant: William Marsh Rice University, (58) Field of Classification Search Houston, TX (US) None See application file for complete search history. (72) Inventors: Ka-Yiu San, Houston, TX (US); Dan Wang, Houston, TX (US) (56) References Cited (73) Assignee: William Marsh Rice University, U.S. PATENT DOCUMENTS Houston, TX (US) 9,994,881 B2 * 6/2018 Gonzalez . Cl2N 9/0006 2016/0090576 Al 3/2016 Garg et al. ( *) Notice: Subject to any disclaimer, the term ofthis patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 152 days. WO W02000075343 12/2000 (21) Appl. No.: 15/572,099 WO W02016179572 11/2016 (22) PCT Filed: May 7, 2016 OTHER PUBLICATIONS (86) PCT No.: PCT/US2016/031386 Choi, K. H., R. J. Heath, and C. 0. Rock. 2000. 13-Ketoacyl-acyl carrier protein synthase III (FabH) is a determining factor in § 371 (c)(l), branched-chain fatty acid biosynthesis. J. Bacteriol. 182:365-370. (2) Date: Nov. 6, 2017 He, X., and K. A. Reynolds. 2002. Purification, characterization, and identification of novel inhibitors of the beta-ketoacyl-acyl (87) PCT Pub. No.: WO2016/179572 carrier protein synthase III (FabH) from Staphylococcus aureus.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • DISSERTATION PROTEOMIC PROFILING of the RAT RENAL PROXIMAL CONVOLUTED TUBULE in RESPONSE to CHRONIC METABOLIC ACIDOSIS Submitted
    DISSERTATION PROTEOMIC PROFILING OF THE RAT RENAL PROXIMAL CONVOLUTED TUBULE IN RESPONSE TO CHRONIC METABOLIC ACIDOSIS Submitted by Dana Marie Freund Department of Biochemistry and Molecular Biology In partial fulfillment of the requirements For the Degree of Doctor of Philosophy Colorado State University Fort Collins, Colorado Spring 2013 Doctoral Committee: Advisor: Norman Curthoys Co-Advisor: Jessica Prenni Jennifer Nyborg Olve Peersen Karen Dobos ABSTRACT PROTEOMIC PROFILING OF THE RAT RENAL PROXIMAL CONVOLUTED TUBULE IN RESPONSE TO CHRONIC METABOLIC ACIDOSIS The human kidneys contain more than one million glomeruli which filter nearly 200 liters of plasma per day. The proximal tubule is the segment of the nephron that immediately follows the glomeruli. This portion of the nephron contributes to fluid, electrolyte and nutrient homeostasis by reabsorbing 60-70% of the filtered water and NaCl and an even greater proportion of NaHCO3. The initial or convoluted portion of the proximal tubule reabsorbs nearly all of the nutrients in the glomerular filtrate and is the site of active secretion and many of the metabolic functions of the kidney. For example, the proximal convoluted tubule is the primary site of renal ammoniagenesis and gluconeogenesis, processes that are significantly activated during metabolic acidosis. Metabolic acidosis is a common clinical condition that is characterized by a decrease in blood pH and bicarbonate concentration. Metabolic acidosis also occurs frequently as a secondary complication, which adversely affects the outcome of patients with various life- threatening conditions. This type of acidosis can occur acutely, lasting for a few hours to a day, or as a chronic condition where acid-base balance is not fully restored.
    [Show full text]
  • Contig Protein Description Symbol Anterior Posterior Ratio
    Table S2. List of proteins detected in anterior and posterior intestine pooled samples. Data on protein expression are mean ± SEM of 4 pools fed the experimental diets. The number of the contig in the Sea Bream Database (http://nutrigroup-iats.org/seabreamdb) is indicated. Contig Protein Description Symbol Anterior Posterior Ratio Ant/Pos C2_6629 1,4-alpha-glucan-branching enzyme GBE1 0.88±0.1 0.91±0.03 0.98 C2_4764 116 kDa U5 small nuclear ribonucleoprotein component EFTUD2 0.74±0.09 0.71±0.05 1.03 C2_299 14-3-3 protein beta/alpha-1 YWHAB 1.45±0.23 2.18±0.09 0.67 C2_268 14-3-3 protein epsilon YWHAE 1.28±0.2 2.01±0.13 0.63 C2_2474 14-3-3 protein gamma-1 YWHAG 1.8±0.41 2.72±0.09 0.66 C2_1017 14-3-3 protein zeta YWHAZ 1.33±0.14 4.41±0.38 0.30 C2_34474 14-3-3-like protein 2 YWHAQ 1.3±0.11 1.85±0.13 0.70 C2_4902 17-beta-hydroxysteroid dehydrogenase 14 HSD17B14 0.93±0.05 2.33±0.09 0.40 C2_3100 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 ABHD5 0.85±0.07 0.78±0.13 1.10 C2_15440 1-phosphatidylinositol phosphodiesterase PLCD1 0.65±0.12 0.4±0.06 1.65 C2_12986 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase delta-1 PLCD1 0.76±0.08 1.15±0.16 0.66 C2_4412 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-2 PLCG2 1.13±0.08 2.08±0.27 0.54 C2_3170 2,4-dienoyl-CoA reductase, mitochondrial DECR1 1.16±0.1 0.83±0.03 1.39 C2_1520 26S protease regulatory subunit 10B PSMC6 1.37±0.21 1.43±0.04 0.96 C2_4264 26S protease regulatory subunit 4 PSMC1 1.2±0.2 1.78±0.08 0.68 C2_1666 26S protease regulatory subunit 6A PSMC3 1.44±0.24 1.61±0.08
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Generated by SRI International Pathway Tools Version 25.0, Authors S
    An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Gcf_000238675-HmpCyc: Bacillus smithii 7_3_47FAA Cellular Overview Connections between pathways are omitted for legibility.
    [Show full text]
  • In Vivo Dual RNA-Seq Analysis Reveals the Basis for Differential Tissue Tropism of Clinical Isolates of Streptococcus Pneumoniae
    In Vivo Dual RNA-Seq Analysis Reveals the Basis for Differential Tissue Tropism of Clinical Isolates of Streptococcus pneumoniae Vikrant Minhas,1,4 Rieza Aprianto,2,4 Lauren J. McAllister,1 Hui Wang,1 Shannon C. David,1 Kimberley T. McLean,1 Iain Comerford,3 Shaun R. McColl,3 James C. Paton,1,5,6,* Jan-Willem Veening,2,5 and Claudia Trappetti,1,5 Supplementary Information Supplementary Table 1. Pneumococcal differential gene expression in the lungs 6 h post-infection, 9-47-Ear vs 9-47M. Genes with fold change (FC) greater than 2 and p < 0.05 are shown. FC values highlighted in blue = upregulated in 9-47-Ear, while values highlighted in red = upregulated in 9- 47M. Locus tag in 9-47- Product padj FC Ear Sp947_chr_00844 Sialidase B 3.08E-10 313.9807 Sp947_chr_02077 hypothetical protein 4.46E-10 306.9412 Sp947_chr_00842 Sodium/glucose cotransporter 2.22E-09 243.4822 Sp947_chr_00841 N-acetylneuraminate lyase 4.53E-09 227.7963 scyllo-inositol 2-dehydrogenase Sp947_chr_00845 (NAD(+)) 4.36E-09 221.051 Sp947_chr_00848 hypothetical protein 1.19E-08 202.7867 V-type sodium ATPase catalytic subunit Sp947_chr_00853 A 1.29E-06 100.5411 Sp947_chr_00846 Beta-glucoside kinase 3.42E-06 98.18951 Sp947_chr_00855 V-type sodium ATPase subunit D 8.34E-06 85.94879 Sp947_chr_00851 V-type sodium ATPase subunit C 2.50E-05 72.46612 Sp947_chr_00843 hypothetical protein 2.17E-05 65.97758 Sp947_chr_00839 HTH-type transcriptional regulator RpiR 3.09E-05 61.28171 Sp947_chr_00854 V-type sodium ATPase subunit B 1.32E-06 50.86992 Sp947_chr_00120 hypothetical protein 3.00E-04
    [Show full text]
  • Health Effects Support Document for Perfluorooctanoic Acid (PFOA)
    United States Office of Water EPA 822-R-16-003 Environmental Protection Mail Code 4304T May 2016 Agency Health Effects Support Document for Perfluorooctanoic Acid (PFOA) Perfluorooctanoic Acid – May 2016 i Health Effects Support Document for Perfluorooctanoic Acid (PFOA) U.S. Environmental Protection Agency Office of Water (4304T) Health and Ecological Criteria Division Washington, DC 20460 EPA Document Number: 822-R-16-003 May 2016 Perfluorooctanoic Acid – May 2016 ii BACKGROUND The Safe Drinking Water Act (SDWA), as amended in 1996, requires the Administrator of the U.S. Environmental Protection Agency (EPA) to periodically publish a list of unregulated chemical contaminants known or anticipated to occur in public water systems and that may require regulation under SDWA. The SDWA also requires the Agency to make regulatory determinations on at least five contaminants on the Contaminant Candidate List (CCL) every 5 years. For each contaminant on the CCL, before EPA makes a regulatory determination, the Agency needs to obtain sufficient data to conduct analyses on the extent to which the contaminant occurs and the risk it poses to populations via drinking water. Ultimately, this information will assist the Agency in determining the most appropriate course of action in relation to the contaminant (e.g., developing a regulation to control it in drinking water, developing guidance, or deciding not to regulate it). The PFOA health assessment was initiated by the Office of Water, Office of Science and Technology in 2009. The draft Health Effects Support Document for Perfluoroctanoic Acid (PFOA) was completed in 2013 and released for public comment in February 2014.
    [Show full text]
  • The Role of Alpha Oxidation in Lipid Metabolism, 2017
    THE ROLE OF ALPHA OXIDATION IN LIPID METABOLISM Benjamin John Jenkins Darwin College Medical Research Council – Human Nutrition Research Department of Biochemistry University of Cambridge This dissertation is submitted for the degree of Doctor of Philosophy July 2018 DECLARATION This dissertation is the result of my own work and includes nothing, which is the outcome of work done in collaboration except as declared in the preface and specified in the text. It is not substantially the same as any that I have submitted, or, is being concurrently submitted for a degree or diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. I further state that no substantial part of my dissertation has already been submitted, or, is being concurrently submitted for any such degree, diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. In accordance with the University of Cambridge guidelines, this thesis does not exceed 60,000 words. Signed: ______________________________________________________________ Date: _______________________________________________________________ Benjamin John Jenkins BSc. MSc. Darwin College, Silver Street, Cambridge, CB3 9EU by i 2014 Word Template Template Friedman Friedman & Morgan Morgan & ii The Role of Alpha Oxidation in Lipid Metabolism, 2017 ABSTRACT Recent findings have shown an inverse association between the circulating levels of pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0) with the risk of pathological development in type 2 diabetes, cardio vascular disease and neurological disorders. From previously published research, it has been said that both these odd chain fatty acids are biomarkers of their dietary intake and are significantly correlated to dietary ruminant fat intake.
    [Show full text]
  • CDH12 Cadherin 12, Type 2 N-Cadherin 2 RPL5 Ribosomal
    5 6 6 5 . 4 2 1 1 1 2 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 A A A A A A A A A A A A A A A A A A A A C C C C C C C C C C C C C C C C C C C C R R R R R R R R R R R R R R R R R R R R B , B B B B B B B B B B B B B B B B B B B , 9 , , , , 4 , , 3 0 , , , , , , , , 6 2 , , 5 , 0 8 6 4 , 7 5 7 0 2 8 9 1 3 3 3 1 1 7 5 0 4 1 4 0 7 1 0 2 0 6 7 8 0 2 5 7 8 0 3 8 5 4 9 0 1 0 8 8 3 5 6 7 4 7 9 5 2 1 1 8 2 2 1 7 9 6 2 1 7 1 1 0 4 5 3 5 8 9 1 0 0 4 2 5 0 8 1 4 1 6 9 0 0 6 3 6 9 1 0 9 0 3 8 1 3 5 6 3 6 0 4 2 6 1 0 1 2 1 9 9 7 9 5 7 1 5 8 9 8 8 2 1 9 9 1 1 1 9 6 9 8 9 7 8 4 5 8 8 6 4 8 1 1 2 8 6 2 7 9 8 3 5 4 3 2 1 7 9 5 3 1 3 2 1 2 9 5 1 1 1 1 1 1 5 9 5 3 2 6 3 4 1 3 1 1 4 1 4 1 7 1 3 4 3 2 7 6 4 2 7 2 1 2 1 5 1 6 3 5 6 1 3 6 4 7 1 6 5 1 1 4 1 6 1 7 6 4 7 e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m
    [Show full text]